Conversely, the combination of NLR with PD-L1 tumor proportion score as assessed by IHC or soluble PD-L1 in the blood is inversely associated with the efficacy of anti-PD-(L)1 immunotherapy [171]. This evidence concerns the gene CD274 and neoplasm.